30
Participants
Start Date
October 22, 2024
Primary Completion Date
June 30, 2026
Study Completion Date
December 31, 2026
Nimodipine Capsules
Two times 30 mg nimodipine or placebo will be administered orally 45 minutes prior to the start of the 5G FR1 exposure. The verum and placebo capsules will look the same, in order to preserve the double-blinding.
5G RF-EMF
Participants will be exposed to a standardized electromagnetic field of the latest mobile radio standard (5G) or a sham field for 30 minutes on each of the experimental nights. The active field is characterized by 3.6 GHz frequency \[TDD\] with 100 MHz bandwidth, 12-14 Hz modulation and is comparable to a phone call with a commercially available, modern cell phone. Both the 5G and sham exposures are performed with the same exposure apparatus, according to a double-blind study design.
RECRUITING
University of Zurich, Institute of Pharmacology and Toxicology, Zurich
Federal Office for the Environment, Switzerland
OTHER_GOV
Hans-Peter Landolt
OTHER